That is, depression comorbid with ACS also leads to very high disease burden, and is difficult to treat [21, 22], and assaying homocysteine and MTHFR genotype might allow more focused interventions for the prevention or management of depressive disorder in the late phase of ACS in more susceptible sub-groups. The gene discussed is MTHFR; the disease is depressive disorder.